{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:30:55Z","timestamp":1787009455209,"version":"build-2736575974"},"reference-count":62,"publisher":"Oxford University Press (OUP)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Mitotane (Lysodren, o,p'-DDD [1-(o-chlorophenyl)-1-(p-chlorophenyl)-2,2-dichloroethane)] is currently the only United States Food and Drug Administration and European Medicines Agency-approved product for the treatment of adrenocortical carcinoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Observations<\/jats:title>\n                    <jats:p>Mitotane is challenging to administer; however, its toxicities (specifically adrenal insufficiency) are well known, and the management of adverse consequences has established approaches. While often viewed through the prism of a cytotoxic agent, it can also interfere with hormone production making it a valuable asset in managing functional ACC. A recently completed prospective trial has shed some light on its use in the adjuvant setting, but further clarity is needed. Many think mitotane has a role in the advanced or metastatic setting, although prospective data are lacking and retrospective analyses are often difficult to interpret.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and relevance<\/jats:title>\n                    <jats:p>When used carefully and thoughtfully, especially in patients with hormonal excess, mitotane is an important component of the treatment armamentarium for ACC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyae084","type":"journal-article","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T08:27:44Z","timestamp":1715243264000},"page":"747-760","source":"Crossref","is-referenced-by-count":26,"title":["A review of mitotane in the management of adrenocortical cancer"],"prefix":"10.1093","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9710-4030","authenticated-orcid":false,"given":"Jaydira","family":"Del Rivero","sequence":"first","affiliation":[{"name":"Developmental Therapeutics Branch, National Cancer Institute, National Institutes of Health , Bethesda, MD 20892 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2262-0011","authenticated-orcid":false,"given":"Tobias","family":"Else","sequence":"additional","affiliation":[{"name":"Division of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, University of Michigan Medical School , Ann Arbor, MI 48104 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8020-8623","authenticated-orcid":false,"given":"Julie","family":"Hallanger-Johnson","sequence":"additional","affiliation":[{"name":"Endocrine Oncology Program, H. Lee Moffitt Cancer Center , Tampa, FL 33612 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3341-582X","authenticated-orcid":false,"given":"Katja","family":"Kiseljak-Vassiliades","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Metabolism and Diabetes, Department of Medicine, University of Colorado School of Medicine at Colorado Anschutz Medical Campus Aurora , CO 80309 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitya","family":"Raj","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York , NY 10065 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2688-4556","authenticated-orcid":false,"given":"Diane","family":"Reidy-Lagunes","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York , NY 10065 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy","family":"Srinivas","sequence":"additional","affiliation":[{"name":"Stanford University School of Medicine , Stanford, CA 94305 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Gilbert","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Vanderbilt University School of Medicine , Nashville, TN 37203 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0314-9252","authenticated-orcid":false,"given":"Anand","family":"Vaidya","sequence":"additional","affiliation":[{"name":"Center for Adrenal Disorders, Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women\u2019s Hospital, Harvard Medical School , Boston, MA 02115 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Aboujaoude","sequence":"additional","affiliation":[{"name":"Rutgers University , Piscataway, NJ 08854 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9332-2524","authenticated-orcid":false,"given":"Irina","family":"Bancos","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, Metabolism and Nutrition and Department of Laboratory Medicine and Pathology, Mayo Clinic , Rochester, MN 55905 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8083-2688","authenticated-orcid":false,"given":"Antonio","family":"Tito Fojo","sequence":"additional","affiliation":[{"name":"Columbia University , New York, NY 10027 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,22]]},"reference":[{"issue":"5","key":"2024090704210307100_CIT0001","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1007\/s00268-005-0329-x","article-title":"Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress","volume":"30","author":"Kebebew","year":"2006","journal-title":"World J Surg"},{"issue":"2","key":"2024090704210307100_CIT0002","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.beem.2008.10.008","article-title":"Clinical management of adrenocortical carcinoma","volume":"23","author":"Fassnacht","year":"2009","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"6","key":"2024090704210307100_CIT0003","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1053\/j.seminoncol.2010.10.011","article-title":"Practical considerations in the evaluation and management of adrenocortical cancer","volume":"37","author":"Balasubramaniam","year":"2010","journal-title":"Semin Oncol"},{"issue":"3","key":"2024090704210307100_CIT0004","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/MED.0b013e3282fdf4c0","article-title":"Adjunctive treatment of adrenocortical carcinoma","volume":"15","author":"Terzolo","year":"2008","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"5","key":"2024090704210307100_CIT0005","first-page":"387","article-title":"Severe adrenal cortical atrophy (cytotoxic) and hepatic damage produced in dogs by feeding 2,2-bis(parachlorophenyl)-1,1-dichloroethane (DDD or TDE)","volume":"48","author":"Nelson","year":"1949","journal-title":"Arch Pathol (Chic)"},{"issue":"6755","key":"2024090704210307100_CIT0006","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S0140-6736(53)90992-1","article-title":"Therapy in Cushing\u2019s syndrome","volume":"1","author":"Sheehan","year":"1953","journal-title":"Lancet"},{"issue":"5","key":"2024090704210307100_CIT0007","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/1097-0142(195609\/10)9:5<940::AID-CNCR2820090513>3.0.CO;2-D","article-title":"The effects of DDD (1, 1-dichloro-2, 2-bis-(p-chlorophenyl)ethane) on the human adrenal; attempts to use an adrenal-destructive agent in the treatment of disseminated mammary and prostatic cancer","volume":"9","author":"Bloch","year":"1956","journal-title":"Cancer"},{"issue":"4","key":"2024090704210307100_CIT0008","first-page":"310","article-title":"Studies on DDD, 2,2-bis (parachlorophenyl)-1,1-dichloroethane","volume":"15","author":"Nichols","year":"1957","journal-title":"Exp Med Surg"},{"issue":"3","key":"2024090704210307100_CIT0009","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1210\/endo-62-3-326","article-title":"The chemical fractionation of an adrenocorticolytic drug","volume":"62","author":"Cueto","year":"1958","journal-title":"Endocrinology"},{"issue":"3","key":"2024090704210307100_CIT0010","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1210\/endo-62-3-334","article-title":"Biological studies on an adrenocorticolytic agent and the isolation of the active components","volume":"62","author":"Cueto","year":"1958","journal-title":"Endocrinology"},{"issue":"4","key":"2024090704210307100_CIT0011","doi-asserted-by":"crossref","first-page":"672","DOI":"10.7326\/0003-4819-53-4-672","article-title":"Chemotherapy of adrenocortical cancer with o,p\u2019DDD","volume":"53","author":"Bergenstal","year":"1960","journal-title":"Ann Intern Med"},{"issue":"6","key":"2024090704210307100_CIT0012","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s002800050610","article-title":"Adrenal proteins bound by a reactive intermediate of mitotane","volume":"39","author":"Cai","year":"1997","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"2024090704210307100_CIT0013","first-page":"1319","article-title":"Cytochrome P450-catalyzed binding of 3-methylsulfonyl-DDE and o,p\u02b9-DDD in human adrenal zona fasciculata\/reticularis","volume":"87","author":"Lindhe","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2024090704210307100_CIT0014","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1210\/clinem\/dgz001","article-title":"The efficacy of mitotane in human primary adrenocortical carcinoma cultures","volume":"105","author":"van Koetsveld","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2024090704210307100_CIT0015","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s40262-020-00913-y","article-title":"Population pharmacokinetic and pharmacogenetic analysis of mitotane in patients with adrenocortical carcinoma: towards individualized dosing","volume":"60","author":"Yin","year":"2021","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"2024090704210307100_CIT0016","first-page":"266","article-title":"Sex differences on mitotane concentration and treatment outcome in patients with adrenocortical carcinoma","volume":"11","author":"Allegra","year":"2021","journal-title":"Life (Basel)"},{"issue":"12","key":"2024090704210307100_CIT0017","doi-asserted-by":"crossref","first-page":"4759","DOI":"10.1210\/jc.2013-2281","article-title":"Comparison of two mitotane starting dose regimens in patients with advanced adrenocortical carcinoma","volume":"98","author":"Kerkhofs","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2024090704210307100_CIT0018","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3390\/pharmaceutics11110566","article-title":"Population pharmacokinetics modelling and simulation of mitotane in patients with adrenocortical carcinoma: an individualized dose regimen to target all patients at three months","volume":"11","author":"Cazaubon","year":"2019","journal-title":"Pharmaceutics"},{"issue":"4","key":"2024090704210307100_CIT0019","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/PAS.0b013e31820bcf21","article-title":"The argument for mitotic rate-based grading for the prognostication of adrenocortical carcinoma","volume":"35","author":"Giordano","year":"2011","journal-title":"Am J Surg Pathol"},{"key":"2024090704210307100_CIT0020"},{"issue":"23","key":"2024090704210307100_CIT0021","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1056\/NEJMoa063360","article-title":"Adjuvant mitotane treatment for adrenocortical carcinoma","volume":"356","author":"Terzolo","year":"2007","journal-title":"N Engl J Med"},{"issue":"4","key":"2024090704210307100_CIT0022","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1210\/jc.2016-2894","article-title":"Long-term outcomes of adjuvant mitotane therapy in patients with radically resected adrenocortical carcinoma","volume":"102","author":"Berruti","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2024090704210307100_CIT0023","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1210\/jc.2013-2856","article-title":"Adjuvant therapies and patient and tumor characteristics associated with survival of adult patients with adrenocortical carcinoma","volume":"99","author":"Else","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2024090704210307100_CIT0024","first-page":"963","article-title":"An eleven-year experience with adrenocortical carcinoma","volume":"112","author":"Pommier","year":"1992","journal-title":"Surgery"},{"issue":"Supplement_1","key":"2024090704210307100_CIT0025","doi-asserted-by":"crossref","first-page":"A166","DOI":"10.1210\/jendso\/bvab048.336","article-title":"Results of the ADIUVO study, the first randomized trial on adjuvant mitotane in adrenocortical carcinoma patients","volume":"5","author":"Terzolo","year":"2021","journal-title":"J Endocr Soc"},{"issue":"4","key":"2024090704210307100_CIT0026","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-18-0608","article-title":"European Society of Endocrinology Clinical practice guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European network for the study of adrenal tumors","volume":"179","author":"Fassnacht","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"2024090704210307100_CIT0027","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s00423-010-0698-y","article-title":"Proposal for modification of the ENSAT staging system for adrenocortical carcinoma using tumor grade","volume":"395","author":"Miller","year":"2010","journal-title":"Langenbecks Arch Surg"},{"issue":"6","key":"2024090704210307100_CIT0028","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/1097-0142(20010915)92:6<1385::AID-CNCR1461>3.0.CO;2-2","article-title":"Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p\u2019DDD) levels on the treatment of patients with adrenocortical carcinoma","volume":"92","author":"Baudin","year":"2001","journal-title":"Cancer"},{"issue":"10","key":"2024090704210307100_CIT0029","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S2213-8587(23)00193-6","article-title":"Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study","volume":"11","author":"Terzolo","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"2024090704210307100_CIT0030","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1634\/theoncologist.2016-0459","article-title":"Complete responses to mitotane in metastatic adrenocortical carcinoma-a new look at an old drug","volume":"22","author":"Reidy-Lagunes","year":"2017","journal-title":"Oncologist"},{"issue":"3","key":"2024090704210307100_CIT0031","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/00007611-198603000-00037","article-title":"Influence of mitotane on the hypoprothrombinemic effect of warfarin","volume":"79","author":"Cuddy","year":"1986","journal-title":"South Med J"},{"issue":"1","key":"2024090704210307100_CIT0032","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1365-2265.1989.tb00453.x","article-title":"Hepatic microsomal enzyme induction and adrenal crisis due to o, p\u02b9DDD therapy for metastatic adrenocortical carcinoma","volume":"31","author":"Hague","year":"1989","journal-title":"Clin Endocrinol"},{"issue":"4","key":"2024090704210307100_CIT0033","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1530\/EJE-10-0956","article-title":"Mitotane has a strong and a durable inducing effect on CYP3A4 activity","volume":"164","author":"van Erp","year":"2011","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2024090704210307100_CIT0034","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1210\/jc.2012-2851","article-title":"Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5\u03b1-reductase, explaining the need for personalized glucocorticoid and androgen replacement","volume":"98","author":"Chortis","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2024090704210307100_CIT0035","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1365-2265.2011.04214.x","article-title":"Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma","volume":"75","author":"Kroiss","year":"2011","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"23","key":"2024090704210307100_CIT0036","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","article-title":"Combination chemotherapy in advanced adrenocortical carcinoma","volume":"366","author":"Fassnacht","year":"2012","journal-title":"N Engl J Med"},{"issue":"10","key":"2024090704210307100_CIT0037","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1002\/(SICI)1097-0142(19981115)83:10<2194::AID-CNCR19>3.0.CO;2-3","article-title":"Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer","volume":"83","author":"Berruti","year":"1998","journal-title":"Cancer"},{"issue":"9","key":"2024090704210307100_CIT0038","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1002\/cncr.10487","article-title":"A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist","volume":"94","author":"Abraham","year":"2002","journal-title":"Cancer"},{"issue":"1","key":"2024090704210307100_CIT0039","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1200\/JCO.19.01586","article-title":"PD-1 blockade in advanced adrenocortical carcinoma","volume":"38","author":"Raj","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"2024090704210307100_CIT0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-019-0722-x","article-title":"Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma","volume":"7","author":"Habra","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"1","key":"2024090704210307100_CIT0041","first-page":"1","article-title":"Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial","volume":"6","author":"Le Tourneau","year":"2018","journal-title":"J Immunother Ccancer"},{"issue":"5","key":"2024090704210307100_CIT0042","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/bjc.1994.183","article-title":"Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients","volume":"69","author":"Haak","year":"1994","journal-title":"Br J Cancer"},{"issue":"1","key":"2024090704210307100_CIT0043","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1677\/ERC-09-0190","article-title":"The long-term survival in adrenocortical carcinoma with active surgical management and use of monitored mitotane","volume":"17","author":"Wangberg","year":"2010","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"2024090704210307100_CIT0044","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1210\/jcem-26-3-268","article-title":"Remission in Cushing\u2019s syndrome with o,p\u02b9-DDD","volume":"26","author":"Southren","year":"1966","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2024090704210307100_CIT0045","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s13318-021-00700-5","article-title":"The challenging pharmacokinetics of mitotane: an old drug in need of new packaging","volume":"46","author":"Haider","year":"2021","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"3","key":"2024090704210307100_CIT0046","doi-asserted-by":"crossref","first-page":"740","DOI":"10.3390\/cancers12030740","article-title":"Mitotane concentrations influence outcome in patients with advanced adrenocortical carcinoma","volume":"12","author":"Puglisi","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"Supplement 4","key":"2024090704210307100_CIT0047","doi-asserted-by":"crossref","first-page":"S505","DOI":"10.1016\/j.annonc.2020.08.467","article-title":"Prognostic value of early total, free and bound to lipoprotein fractions plasma mitotane measurements in advanced adrenocortical carcinoma at the time of mitotane initiation: a prospective study of the ENDOCAN-COMETE-cancer network","volume":"31","author":"Naman","year":"2020","journal-title":"Ann Onc"},{"issue":"15","key":"2024090704210307100_CIT0048","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1056\/NEJM196910092811501","article-title":"Treatment of Cushing\u2019s disease. Correction of hypercortisolism by o,p\u2019DDD without induction of aldosterone deficiency","volume":"281","author":"Temple","year":"1969","journal-title":"N Engl J Med"},{"issue":"8","key":"2024090704210307100_CIT0049","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1177\/1060028020968808","article-title":"Osilodrostat: a novel steroidogenesis inhibitor to treat Cushing\u2019s Disease","volume":"55","author":"Dougherty","year":"2021","journal-title":"Ann Pharmacother"},{"issue":"3","key":"2024090704210307100_CIT0050","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/phar.1202","article-title":"Mifepristone for management of Cushing\u2019s Syndrome","volume":"33","author":"Morgan","year":"2013","journal-title":"Pharmacotherapy"},{"issue":"2","key":"2024090704210307100_CIT0051","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/cen.14345","article-title":"Metabolic and hormonal side effects of mitotane treatment for adrenocortical carcinoma: a retrospective study in 50 Danish patients","volume":"94","author":"Vikner","year":"2021","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"19","key":"2024090704210307100_CIT0052","doi-asserted-by":"crossref","first-page":"5001","DOI":"10.3390\/cancers13195001","article-title":"Metabolic and endocrine toxicities of mitotane: a systematic review","volume":"13","author":"Bianchini","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"9","key":"2024090704210307100_CIT0053","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.3390\/cancers12092615","article-title":"Unwanted hormonal and metabolic effects of postoperative adjuvant mitotane treatment for adrenocortical cancer","volume":"12","author":"Basile","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"4","key":"2024090704210307100_CIT0054","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.path.2019.08.010","article-title":"Treatment of adrenocortical carcinoma","volume":"12","author":"Vaidya","year":"2019","journal-title":"Surg Pathol Clin"},{"issue":"4","key":"2024090704210307100_CIT0055","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1530\/EJE-17-0452","article-title":"Effects of mitotane on the hypothalamic-pituitary-adrenal axis in patients with adrenocortical carcinoma","volume":"177","author":"Reimondo","year":"2017","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2024090704210307100_CIT0056","doi-asserted-by":"crossref","first-page":"639","DOI":"10.3390\/cancers12030639","article-title":"Recovery of adrenal insufficiency is frequent after adjuvant mitotane therapy in patients with adrenocortical carcinoma","volume":"12","author":"Poirier","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"4","key":"2024090704210307100_CIT0057","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/cen.12868","article-title":"Mitotane treatment in patients with adrenocortical cancer causes central hypothyroidism","volume":"84","author":"Russo","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"11","key":"2024090704210307100_CIT0058","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.4158\/DSCR-2020-0567","article-title":"American association of clinical endocrinology disease state clinical review on the evaluation and management of adrenocortical carcinoma in an adult: a practical approach","volume":"26","author":"Kiseljak-Vassiliades","year":"2020","journal-title":"Endocr Pract"},{"issue":"4","key":"2024090704210307100_CIT0059","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1530\/EJE-12-0358","article-title":"Efficiency and tolerance of mitotane in Cushing\u2019s disease in 76 patients from a single center","volume":"167","author":"Baudry","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2024090704210307100_CIT0060","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1677\/ERC-08-0103","article-title":"Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly","volume":"15","author":"Daffara","year":"2008","journal-title":"Endocr Relat Cancer"},{"issue":"9","key":"2024090704210307100_CIT0061","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1200\/JCO.1992.10.9.1504","article-title":"Neuropsychologic and neurologic side effects of mitotane and reversibility of symptoms","volume":"10","author":"Lanser","year":"1992","journal-title":"J Clin Oncol"},{"issue":"40","key":"2024090704210307100_CIT0062","doi-asserted-by":"crossref","first-page":"e22620","DOI":"10.1097\/MD.0000000000022620","article-title":"A case report of neurological adverse events caused by short-term and low-dose treatment of mitotane: the role of therapeutic drug monitoring","volume":"99","author":"Liu","year":"2020","journal-title":"Medicine (Baltim)"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/9\/747\/59036728\/oyae084.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/9\/747\/59036728\/oyae084.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T01:06:44Z","timestamp":1725671204000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/29\/9\/747\/7717913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,22]]},"references-count":62,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,7,22]]},"published-print":{"date-parts":[[2024,9,6]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyae084","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,7,22]]}}}